Jump to content

Kahn Sagol Maccabi

Edit links
From Wikipedia, the free encyclopedia

The Kahn-Sagol-Maccabi for Research and Innovation
מכון קאהן-סגול-מכבי למחקר ולחדשנות (Hebrew)
TypeMedical research
Established2016
Location
Israel
Websitewww.ksminnovation.com

The Kahn-Sagol-Maccabi (KSM) for Research and Innovation (in Hebrew: מכון קאהן-סגול-מכבי למחקר ולחדשנות) is the Research and Innovation Center of Maccabi Healthcare Services.[1]

History

[edit]

Founded in 2016 by Maccabi Health Services with the key support of Morris Kahn and Sami Sagaol, KSM promotes excellence in medical research.[2]

It wasa formerly headed by Prof. Varda Shalev and is currently headed by Dr. Tal Patalon.[3]

Activities and services

[edit]

Medical studies

[edit]

KSM Center strives to enhance healthcare systems through independent research and partnerships with international researchers,[4] academic institutions, pharmaceutical companies, start-ups and technology firms.[5][6]

Since its inception, the center has conducted hundreds of studies,[7] resulting in the development of tools for both patients and healthcare providers.[8] These studies have influenced medical policies in several countries, particularly during the COVID-19 pandemic.[9]

Notable studies conducted under KSM's auspices include:

  • Studies on the coronavirus epidemic – During the COVID-19 pandemic, several international scientific studies based on the Maccabi databases were conducted by the center, Including studies on repeated infection in children,[10] repeated infection in adults,[11] natural vaccination,[12][9][13] reduction of transmission[14] the decline in the effect of the third vaccine[15] the effect of the vaccine on intra-domestic infection[16] and on patients with Coeliac disease.[17]
  • Research on mpox – In 2023, a study on mpox based on KSM's analysis and database was published.[18]
  • Research on Parvovirus B19 – In 2023, a study on a local outbreak of parvovirus was published.[19]
  • Research on autism – In 2023, a study on late diagnosis of autism was published.[20]
  • Research on cancer – In 2023, a study of the effects of palbociclib treatment on the lifespan of patients with breast cancer was published.[21]

Medical database

[edit]

KSM's research activities are based on independent efforts, as well as the extensive medical knowledge and database of Maccabi Health Services.[22] This database, compiled over three decades and anonymized, encompasses digital records of 2.7 million insured individuals.[23]

In addition to its in-house research,[24] the Center offers global researchers access to conduct studies, analyses [30] and medical prediction,[25] based on this comprehensive database.[26]

KSM's innovation and big data department leverages databases and artificial intelligence technologies,[27][28] facilitating a wide range of research opportunities, analysis and medical prediction.[29]

Biobank

[edit]

The KSM Center has established the Tipa BioBank,[30] Israel's largest biobank[31] housing over a million genetic samples for research purposes.[32][8]

The purpose of this initiative is to develop tools for early disease detection through genetic[33] and biological studies.[34] A central feature of this effort is the creation of a repository of biological samples (e.g., blood, urine, etc.), enabling researchers to investigate how genetic profiles influence disease risk and treatment.[35]

Main publications

[edit]

References

[edit]
  1. ^ The Kahn-Sagol-Maccabi (KSM) Institute for Research and Innovation
  2. ^ "Kahn Sagol Maccabi". Guidestar. Retrieved 9 November 2023.
  3. ^ Big data unit Kahn-Sagol-Maccabi (KSM)
  4. ^ Neesha Salian, SEHA and Israel’s leading HMO announce collaboration in research and digital health development, Gulf Business, 13 July 2022
  5. ^ Maccabi’s KSM Research and Innovation Center Announces Partnership with Rhino Health to Facilitate Healthcare Data Collaborations, Accesswire 25 October 2022
  6. ^ PrognomiQ, Maccabi Health Collaborating on Cancer Biomarker Development, 360dx.com, 21 June 2022
  7. ^ Professional publications, KSM Research and Innovation Center
  8. ^ a b Rubinstein, Carrie (9 September 2022). "Small-Big Data: A Healthcare Revolution In The Making". Forbes. Retrieved 26 October 2023.
  9. ^ a b Patalon, Tal; Saciuk, Yaki; Perez, Galit; Peretz, Asaf; Ben-Tov, Amir; Gazit, Sivan (2023). "Dynamics of Naturally Acquired Immunity Against Severe Acute Respiratory Syndrome Coronavirus 2 in Children and Adolescents". The Journal of Pediatrics. 257. doi:10.1016/j.jpeds.2023.02.016. PMC 9981270. PMID 36870558.
  10. ^ Gazit, Sivan; Saciuk, Yaki; Perez, Galit; Peretz, Asaf; Ben-Tov, Amir; Stuart, Elizabeth A.; Patalon, Tal (2023). "Hybrid immunity against reinfection with SARS-CoV-2 following a previous SARS-CoV-2 infection and single dose of the BNT162b2 vaccine in children and adolescents: A target trial emulation". The Lancet Microbe. 4 (7): e495–e505. doi:10.1016/S2666-5247(23)00103-9. PMC 10101759. PMID 37062294.
  11. ^ Gazit, S.; Shlezinger, R.; Perez, G.; Lotan, R.; Peretz, A.; Ben-Tov, A.; Herzel, E.; Alapi, H.; Cohen, D.; Muhsen, K.; Chodick, G.; Patalon, T. (2022). "The Incidence of SARS-CoV-2 Reinfection in Persons with Naturally Acquired Immunity with and Without Subsequent Receipt of a Single Dose of BNT162b2 Vaccine: A Retrospective Cohort Study". Annals of Internal Medicine. 175 (5): 674–681. doi:10.7326/M21-4130. PMC 8855786. PMID 35157493.
  12. ^ Patalon, Tal; Saciuk, Yaki; Perez, Galit; Peretz, Asaf; Ben-Tov, Amir; Gazit, Sivan (2023). "Dynamics of Naturally Acquired Immunity Against Severe Acute Respiratory Syndrome Coronavirus 2 in Children and Adolescents". The Journal of Pediatrics. 257. doi:10.1016/j.jpeds.2023.02.016. PMC 9981270. PMID 36870558.
  13. ^ Patalon, Tal; Saciuk, Yaki; Perez, Galit; Peretz, Asaf; Ben-Tov, Amir; Gazit, Sivan (2023). "Dynamics of Naturally Acquired Immunity Against Severe Acute Respiratory Syndrome Coronavirus 2 in Children and Adolescents". The Journal of Pediatrics. 257. doi:10.1016/j.jpeds.2023.02.016. PMC 9981270. PMID 36870558.
  14. ^ van Boven, Michiel; van Dorp, Christiaan H.; Westerhof, Ilse; et al. (29 January 2024). "Estimation of introduction and transmission rates of SARS-CoV-2 in a prospective household study". PLOS Computational Biology. 20 (1): e1011832. doi:10.1371/journal.pcbi.1011832. ISSN 1553-7358. medRxiv 10.1101/2023.06.02.23290879. PMC 10852262. PMID 38285727.
  15. ^ Patalon, Tal; Saciuk, Yaki; Peretz, Asaf; Perez, Galit; Lurie, Yoav; Maor, Yasmin; Gazit, Sivan (2022). "Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine". Nature Communications. 13 (1): 3203. Bibcode:2022NatCo..13.3203P. doi:10.1038/s41467-022-30884-6. PMC 9184525. PMID 35680872.
  16. ^ Prunas, Ottavia; Warren, Joshua L.; Crawford, Forrest W.; Gazit, Sivan; Patalon, Tal; Weinberger, Daniel M.; Pitzer, Virginia E. (2022). "Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel". Science. 375 (6585): 1151–1154. Bibcode:2022Sci...375.1151P. doi:10.1126/science.abl4292. PMC 9261115. PMID 35084937.
  17. ^ Ben-Tov, Amir; Lebwohl, Benjamin; Banon, Tamar; Chodick, Gabriel; Kariv, Revital; Assa, Amit; Gazit, Sivan; Patalon, Tal (2023). "BNT162b2 mRNA COVID-19 Vaccine Effectiveness in Patients with Coeliac Disease Autoimmunity: Real-World Data from Mass Vaccination Campaign". Viruses. 15 (9): 1968. doi:10.3390/v15091968. PMC 10534420. PMID 37766374.
  18. ^ Patalon, Tal; Perez, Galit; Saciuk, Yaki; Refaeli, Ziva; Gazit, Sivan (2023). "Mpox Patient Journey in Israel". Microorganisms. 11 (4): 1042. doi:10.3390/microorganisms11041042. PMC 10145053. PMID 37110465.
  19. ^ Patalon, Tal; Saciuk, Yaki; Trotzky, Daniel; Pachys, Gal; Ben-Tov, Amir; Segal, Yaakov; Gazit, Sivan (2023). "An Outbreak of Parvovirus B19 in Israel". Viruses. 15 (11): 2261. doi:10.3390/v15112261. PMC 10674631. PMID 38005937.
  20. ^ Davidovitch, Michael; Gazit, Sivan; Patalon, Tal; Leitner, Yael; Rotem, Ran S. (2023). "Late diagnosis of autism spectrum disorder—Journey, parents' concerns, and sex influences". Autism Research. 16 (2): 294–301. doi:10.1002/aur.2869. PMID 36495248. S2CID 254561408.
  21. ^ Moser, Sarah Sharman; Mazursky, Orr Friedman; Shalev, Hadas; Apter, Lior; Chodick, Gabriel; Siegelmann-Danieli, Nava (2023). "Real-world outcomes of patients with metastatic endocrine-responsive breast cancer receiving palbociclib-based combinations". Future Oncology. 19 (21): 1473–1483. doi:10.2217/fon-2023-0176. PMID 37529919.
  22. ^ Valo Health, KSM research and innovation center and Valo health announce first of its kind multiyear collaboration to spearhead preventive care and personalized medicine for patients, 19 Sep 2022
  23. ^ Kraus, Yair (1 August 2023). ""Artificial intelligence is going to lead to a change the likes of which we haven't seen in years in the world of medicine"". Ynet. Retrieved 9 November 2023.
  24. ^ Yanko, Adir (25 March 2021). "A significant increase in the diagnosis of young celiac patients in Israel – what are the reasons for this?". Ynet. Retrieved 26 October 2023.
  25. ^ Yechezkel, Matan; Mofaz, Merav; Painsky, Amichai; Patalon, Tal; Gazit, Sivan; Shmueli, Erez; Yamin, Dan (2023). "Safety of the fourth COVID-19 BNT162b2 mRNA (Second booster) vaccine: A prospective and retrospective cohort study". The Lancet Respiratory Medicine. 11 (2): 139–150. doi:10.1016/S2213-2600(22)00407-6. PMC 9889528. PMID 36410364.
  26. ^ Weinerb, Gali (1 December 2020). "Predicting illnesses and hospitalizations: the vision of the director of the Maccabi Research Institute". Globes. Retrieved 26 October 2023.
  27. ^ Danny Sullivan, Longevity AI partners with Israel’s leading HMO, Technology, 4 April 2023
  28. ^ IBEX Introduces Galen Gastric, World’s First AI-Powered Solution For Gastrointestinal Cancer Diagnostics, At Maccabi Healthcare Services, AIthority.com, 24 August 2021
  29. ^ Suresh, Somasetty (25 October 2023). "New Study Shows Pfizer COVID-19 Vaccine Equally Effective for Patients with Celiac Disease". Express Healthcare Management. Retrieved 26 October 2023.
  30. ^ The Tipa Biobank, Kahn-Sagol-Maccabi (KSM)
  31. ^ KSM Research And Innovation And Genetika+ Partner To Seek AI Solutions For Personalization Of Depression Treatment, 15 August 2022
  32. ^ "Abu Dhabi DoH and Kahn Sagol Maccabi (KSM) Sign an MoU to Cooperate in Technological Innovation and Healthcare Research". AP news. 1 February 2023. Retrieved 26 October 2023.
  33. ^ G42 Healthcare, KSM enter first UAE-Israel genetic research collaboration – Arabian Business, Arabian Business, 2 March 2022
  34. ^ Rubinstein, Carrie (12 July 2023). "Apparently Getting Smarter Makes Us Healthier: AI And Data Analysis Revolutionize Healthcare". Forbes. Retrieved 26 October 2023.
  35. ^ Israel and UAE to collaborate on cancer and diabetes research, MiddleEastMonitor ,14 July 2022
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Kahn_Sagol_Maccabi&oldid=1253047091"